Critères de non-inclusion : - Medical history or ongoing gastrointestinal disorders that could affect absorption of SAR439859 and/or palbociclib (including difficulties with swallowing capsules)
- Patient with any other cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or any other cancer from which the patient has been disease free for >3 years)
- Patients with known brain metastases and endometrial disorders
- Treatment with anticancer agents (including investigational drugs) less than 2 weeks before first study treatment starts (less than 4 weeks if the anticancer agents were antibodies)
- Prior treatment with another selective ER down-regulator (SERD) (except fulvestrant)
- Inadequate hematological and biochemical lab tests
- Patients with Gilbert disease
-Treatment with human immunodeficiency virus (HIV)-antiviral, antifungal and antioxidant agents less than 2 weeks before study treatment starts
- Treatment with strong and moderate CYP3A inducers/inhibitors within 2 weeks before first study treatment

Part A only:
- Patients with liver metastases only

Parts C and D only:
- Prior therapy with any selective cyclin-dependent kinase (CDK) 4/6 inhibitor
- Treatment with strong and moderate CYP3A inducers or strong CYP3A inhibitors within 2 weeks before first study treatment starts
- Medical conditions requiring concomitant medications that are metabolized by CYP3A

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.